Sareum Holdings, a specialist cancer drug discovery and development business, has entered a co-development agreement with Hebei Medical University Biomedical Engineering Center (HMUBEC), an independent research center, to advance its Aurora+FLT3 cancer program.
Under the terms of the agreement HMUBEC has been granted exclusive rights to carry out pre-clinical and clinical studies within Greater China* to obtain approval for sales in that territory.
Aurora+FLT3 kinase inhibitors have the potential to treat acute myeloid leukaemia (AML, the most common form of adult leukaemia) and various other forms of cancer. Aurora kinase is involved in the control of mitosis (cell division), and FLT3 kinase over-activation is the most common mutation in AML. The pre-clinical development candidate that has been licenced by Sareum to HMUBEC has showed particular promise against a range of haematological cancer models including AML and Acute Lymphoblastic Leukaemia (ALL) with an encouraging early safety profile and positive ADME (absorption, distribution, metabolism, excretion) properties.
Sareum was advised and assisted on this agreement by Cambridge, UK based technology brokerage Link China Pharma Solutions.
Dr. Tim Mitchell, Chief Executive Officer of Sareum Holdings plc, said: "This agreement provides us with significant additional resource, exposure to a major market and the flexibility to undertake our own independent research utilising HMUBEC's findings at any point in the development programme. HMUBEC also has the capability and resources to advance the Aurora+FLT3 programme from pre-clinical all the way through clinical trials and onto the Chinese market. We believe all this provides a good balance of risk and reward for our shareholders and we look forward to working closely with HMUBEC."
Professor Donggang Liu, Deputy General Manager of the Hebei Medical University Science & Technology General Company, said: "We have been very impressed with the results of the studies undertaken on Sareum's Aurora+FLT3 programme so far and we have real confidence in the programme's potential to develop a world class drug to treat several forms of blood cancer. HMUBEC has significant resources and expertise to expedite this research programme, and we look forward to commencing work on this very exciting compound."
*Greater China includes the People's Republic of China, and the special administrative regions of Hong Kong and Macau, and Taiwan region.
Click here for the complete issue.